Research programme: covalent inhibitors - Aurigene Discovery Technologies

Drug Profile

Research programme: covalent inhibitors - Aurigene Discovery Technologies

Alternative Names: AU-002; CDK12 inhibitors; CDK7 inhibitor; KRAS inhibitor; MALT-1 inhibitor

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CD7 antigen inhibitors; Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; KRAS protein inhibitors; MALT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Oct 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 15 Apr 2016 Preclinical trials in Cancer in India (PO) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top